QUALIGEN THERAPEUTICS INC (QLGN) Stock Price & Overview
NASDAQ:QLGN • US74754R3012
The current stock price of QLGN is 3.21 USD. Today QLGN is up by 5.59%. In the past month the price decreased by -15.97%. In the past year, price decreased by -33.55%.
QLGN Key Statistics
- Market Cap
- 6.516M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -8.60
- Dividend Yield
- N/A
QLGN Stock Performance
QLGN Stock Chart
QLGN Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to QLGN. When comparing the yearly performance of all stocks, QLGN is one of the better performing stocks in the market, outperforming 84.64% of all stocks.
QLGN Earnings
QLGN Forecast & Estimates
For the next year, analysts expect an EPS growth of 62.96% and a revenue growth -100% for QLGN
QLGN Groups
Sector & Classification
QLGN Financial Highlights
Over the last trailing twelve months QLGN reported a non-GAAP Earnings per Share(EPS) of -8.6. The EPS increased by 83.49% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -176.92% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
QLGN Ownership
QLGN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.1 | 414.026B | ||
| AMGN | AMGEN INC | 16.73 | 207.692B | ||
| GILD | GILEAD SCIENCES INC | 16.57 | 186.139B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.26 | 123.316B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.5 | 83.604B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.57 | 42.945B | ||
| INSM | INSMED INC | N/A | 31.206B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 12.1 | 27.598B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.69 | 22.521B | ||
| MRNA | MODERNA INC | N/A | 20.646B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 20.138B | ||
| EXAS | EXACT SCIENCES CORP | 308.97 | 19.72B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About QLGN
Company Profile
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company is headquartered in Carlsbad, California. The company went IPO on 2015-06-24. The firm is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.
Company Info
QUALIGEN THERAPEUTICS INC
2042 Corte Del Nogal
Carlsbad CALIFORNIA 92011 US
CEO: Andrew J. Ritter
Employees: 4
Phone: 17609189165
QUALIGEN THERAPEUTICS INC / QLGN FAQ
Can you describe the business of QUALIGEN THERAPEUTICS INC?
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company is headquartered in Carlsbad, California. The company went IPO on 2015-06-24. The firm is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.
What is the current price of QLGN stock?
The current stock price of QLGN is 3.21 USD. The price increased by 5.59% in the last trading session.
Does QUALIGEN THERAPEUTICS INC pay dividends?
QLGN does not pay a dividend.
What is the ChartMill technical and fundamental rating of QLGN stock?
QLGN has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the GICS sector and industry of QLGN stock?
QUALIGEN THERAPEUTICS INC (QLGN) operates in the Health Care sector and the Biotechnology industry.
Can you provide the ownership details for QLGN stock?
You can find the ownership structure of QUALIGEN THERAPEUTICS INC (QLGN) on the Ownership tab.